TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA) Financials
Annual revenue, profitability and per-share results for TEVA PHARMACEUTICAL INDUSTRIES LTD, as reported in SEC filings.
Revenue • FY2025
$17.26B
▲ 4.3%YoY
Net income • FY2025
$1.41B
▲ 186.0%YoY
Gross margin • FY2025
51.8%
Diluted EPS • FY2025
$1.21
▲ 183.4%YoY
Annual income statement
| Period | Revenue | Net income | Gross profit | Dil. EPS | Free cash flow | Op. margin | Rev. growth |
|---|---|---|---|---|---|---|---|
| FY2025 | $17.26B | $1.41B | $8.94B | $1.21 | $1.15B | 12.5% | +4.3% |
| FY2024 | $16.54B | -$1.64B | $8.06B | -$1.45 | $749M | -1.8% | +4.4% |
| FY2023 | $15.85B | -$559M | $7.64B | -$0.50 | $842M | 2.7% | +6.2% |
| FY2022 | $14.93B | -$2.35B | $6.97B | -$2.12 | $1.04B | -14.1% | -6.0% |
Figures as reported in TEVA PHARMACEUTICAL INDUSTRIES LTD's 10-K filings on SEC EDGAR. Fiscal years may differ from calendar years.
Never miss a TEVA filing.
Get an email when TEVA files its next 8-K, Form 4, 10-K or 10-Q with the SEC. Free, no account needed.
Free foreverNo account requiredOne-click unsubscribe
Source: SEC EDGAR.